ResMed Inc. (RMD)
| Market Cap | 36.84B |
| Revenue (ttm) | 5.02B |
| Net Income (ttm) | 1.31B |
| Shares Out | 146.37M |
| EPS (ttm) | 8.91 |
| PE Ratio | 28.25 |
| Forward PE | 24.70 |
| Dividend | $2.12 (0.84%) |
| Ex-Dividend Date | May 8, 2025 |
| Volume | 645,869 |
| Open | 250.72 |
| Previous Close | 249.34 |
| Day's Range | 249.61 - 254.03 |
| 52-Week Range | 179.42 - 263.05 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 259.40 (+3.07%) |
| Earnings Date | Jul 31, 2025 |
About RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on de... [Read more]
Financial Performance
In 2024, ResMed's revenue was $4.69 billion, an increase of 10.95% compared to the previous year's $4.22 billion. Earnings were $1.02 billion, an increase of 13.75%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for RMD stock is "Buy." The 12-month stock price forecast is $259.4, which is an increase of 3.07% from the latest price.
News
ResMed: A Sleeping Giant Hiding In Plain Sight
ResMed dominates an enormous, underdiagnosed market with recurring revenue and digital health leadership, yet trades below its historical earnings multiples, offering compelling value. The company's s...
Top 15 High-Growth Dividend Stocks For June 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in May, gaining 6.45% versus SPY's 6.28% and VIG's 3.61%. The list's year-to-date return is 6.07%, beating SPY every month in 2025, thoug...
Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025
SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the ...
Top 15 High-Growth Dividend Stocks To Consider For May 2025
My Top 15 High-Growth Dividend stocks for April 2025 outperformed SPY and VIG, posting a 0.12% gain versus SPY's -0.87% and VIG's -1.53%. Year-to-date, the Top 15 list returned -0.36%, outperforming V...
Resmed Acquires VirtuOx
Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers Acquisition supports Resmed's growth in virtual care, ...
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast
On Wednesday, ResMed Inc RMD reported that third-quarter adjusted EPS was $2.37, beating the consensus of $2.36.
ResMed: Cornering The Market In Sleep Solutions
ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, e...
ResMed Inc. (RMD) Q3 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD) Q3 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Mick Farrell - Chairman & Chief Executive Officer Salli Schwartz - Chief Investor Relations Offi...
ResMed slightly beats quarterly profit estimates on sleep devices demand
Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025
Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
Resmed Names Salli Schwartz as Chief Investor Relations Officer
Former Illumina, MSCI, and Moody's executive brings extensive experience leading engagement with the global investment community Former Illumina, MSCI, and Moody's executive brings extensive experienc...
Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home ...
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2025 on Wednesday,...
My Top 15 High-Growth Dividend Stocks For April 2025
My Top 15 High-Growth Dividend stocks outperformed SPY and VIG in March, posting a loss of 3.26% compared to SPY's 5.86% and VIG's 4.50%. The April 2025 list offers an average dividend yield of 1.25% ...
New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publ...
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced a compreh...
My Top 15 High-Growth Dividend Stocks For March 2025
The SPDR S&P 500 ETF Trust stumbled in February but managed to maintain a positive return in 2025. The Top 15 dividend growth stocks for March 2025 offer an average dividend yield of 1.13% and appear ...
ResMed's Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep
New insights from 30,026 people across 13 markets show the global scale of poor sleep and its impact on health, work, and relationships New insights from 30,026 people across 13 markets show the globa...
Jan De Witte joins GHO Capital as Operating Partner
Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February...
Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple Wat...
Stock Of The Day: Trading The Range In ResMed
ResMed Inc. RMD shares are consolidating on Monday. This follows Friday's decline of more than 8%.
ResMed Inc. (RMD) Q2 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD) Q2 2025 Earnings Conference Call January 30, 2025 4:30 PM ET Company Participants Mike Ott - Senior Manager, IR Michael Farrell - Chairman and Chief Executive Officer Brett San...
ResMed beats quarterly profit estimates on demand for sleep disorder devices
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025
Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
Top 50 High Quality Dividend Growth Stocks - January 2025
I track 50 high-quality dividend stocks, updating their valuations daily to identify Strong Buy, Buy, Hold, and Trim opportunities based on historical free cash flow trends. Using my quality score and...